Diabetes treatment drug PEG zensetide injection was approved for marketing

Medical Network May 8th, May 7th, NMPA released a message that recently, the agency approved a class of innovative drug PEG-losenadine injection (trade name: Fulaimei) through the priority review and approval process. Listed for use in adults to improve glycemic control in patients with type 2 diabetes.

Polyethylene glycol lozena peptide is a long-acting GLP-1 receptor agonist that promotes glucose-dependent insulin secretion, combined with diet control and exercise , alone or in combination with metformin, to improve blood sugar in adults with type 2 diabetes. control. The launch of PEG lozena peptide injection will provide new treatment for patients with type 2 diabetes